JPMorgan Chase & Co. Boosts Maze Therapeutics (NASDAQ:MAZE) Price Target to $58.00

Maze Therapeutics (NASDAQ:MAZE) had its price target increased by investment analysts at JPMorgan Chase & Co. from $52.00 to $58.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 92.52% from the stock’s current price.

Several other analysts also recently weighed in on the company. Truist Financial initiated coverage on Maze Therapeutics in a research note on Tuesday, March 17th. They set a “buy” rating and a $68.00 target price for the company. HC Wainwright lifted their price target on Maze Therapeutics from $60.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, March 25th. Mizuho upgraded Maze Therapeutics to a “strong-buy” rating in a report on Wednesday, March 11th. Weiss Ratings reissued a “sell (d)” rating on shares of Maze Therapeutics in a research report on Thursday, January 22nd. Finally, Guggenheim raised their price objective on shares of Maze Therapeutics from $46.00 to $58.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Three investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $66.44.

Maze Therapeutics Price Performance

Shares of NASDAQ MAZE traded up $1.12 during trading hours on Tuesday, hitting $30.13. 384,537 shares of the stock were exchanged, compared to its average volume of 682,203. Maze Therapeutics has a one year low of $6.71 and a one year high of $53.65. The company’s 50 day moving average is $45.37 and its 200 day moving average is $37.95. The firm has a market capitalization of $1.50 billion, a P/E ratio of -9.31 and a beta of 4.46.

Maze Therapeutics (NASDAQ:MAZE) last announced its earnings results on Wednesday, March 25th. The company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.08.

Insider Buying and Selling at Maze Therapeutics

In other news, SVP Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $46.04, for a total transaction of $230,200.00. Following the sale, the senior vice president owned 12,965 shares of the company’s stock, valued at approximately $596,908.60. This trade represents a 27.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction on Thursday, January 29th. The stock was sold at an average price of $44.27, for a total transaction of $332,025.00. Following the sale, the insider owned 10,503 shares in the company, valued at $464,967.81. This represents a 41.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 112,500 shares of company stock valued at $5,132,812 in the last quarter.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Janus Henderson Group PLC increased its holdings in shares of Maze Therapeutics by 318.0% during the fourth quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock worth $130,197,000 after buying an additional 2,390,713 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Maze Therapeutics by 218.1% in the third quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock valued at $34,615,000 after buying an additional 915,342 shares in the last quarter. Marshall Wace LLP raised its holdings in shares of Maze Therapeutics by 3,868.5% in the third quarter. Marshall Wace LLP now owns 777,701 shares of the company’s stock valued at $20,166,000 after buying an additional 758,104 shares during the last quarter. Caligan Partners LP bought a new position in shares of Maze Therapeutics in the fourth quarter valued at about $22,794,000. Finally, ArrowMark Colorado Holdings LLC acquired a new position in Maze Therapeutics during the 3rd quarter worth about $14,135,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.